The modest EPS miss is noise for a pre-revenue biotech; the stock will move on SC451 IND filing and SG293 clinical data catalysts expected within 6-9 months. Monitor for IND submission announcements and the EASD symposium on October 2 for UP421 data. The extended cash runway into mid-2027 removes near-term financing overhang.
Price Chart
Executive Summary
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), a narrower loss vs $93.8M ($0.39/share) in Q2 2025, driven by the absence of a prior-year $44.6M impairment. Non-GAAP net loss was $39.7M ($0.13/share), slightly wider than $38.9M ($0.16/share) last year and a 6.9% miss vs the $-0.12 consensus. Cash position improved to $160.5M from $138.4M at year-end 2025, bolstered by $93.3M in net equity proceeds from ATM sales and the Mayo Clinic investment, extending the cash runway into mid-2027. The stock will trade on pipeline catalysts — SC451 IND filing and SG293 first-in-human data expected within 6-9 months — rather than the modest EPS miss, which is a mechanical artifact of share-count dilution for this pre-revenue biotech.
Key Financial Metrics
Key Facts
- Q2 2026 GAAP net loss $63.6M ($0.22/share) vs $93.8M ($0.39/share) in Q2 2025; prior year included $44.6M impairment
- Non-GAAP net loss $39.7M ($0.13/share) vs consensus $-0.12 — a 6.9% miss
- Cash, cash equivalents, and marketable securities $160.5M as of June 30, 2026, up from $138.4M at Dec 31, 2025
- Raised $93.3M net proceeds from ATM stock sales and Mayo Clinic equity investment in Q2 2026
- Expected cash runway into mid-2027
- SC451 (type 1 diabetes) IND and Phase 1/2 trial start expected as early as this year; SG293 (non-Hodgkin lymphoma) first-in-human data expected as early as this year
- NEJM publication of 14-month UP421 data showing islet cell survival without immunosuppression
- Mayo Clinic strategic collaboration advancing SC451 development
- Weighted-average shares outstanding 295.7M in Q2 2026 vs 238.4M in Q2 2025 — 24% dilution
Financial Impact
Q2 2026 GAAP net loss $63.6M; Non-GAAP net loss $39.7M; cash burn $69.3M in H1 2026; $93.3M equity raised
Risk Factors
- Clinical trial delays or negative data for SC451 or SG293
- Further dilution from ATM sales or additional equity financing
- Significant non-cash contingent consideration and success payment liabilities ($175.3M) create earnings volatility
- Historical model performance on SANA shows negative average T+20 alpha (-2.92%) and 44% win rate, suggesting limited near-term trading conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342371 |
| Document: sana-20260810.htm | 0001193125-26-342371 |
| Document: 0001193125-26-342371-index-headers.html | 0001193125-26-342371 |
| Document: 0001193125-26-342371-index.html | 0001193125-26-342371 |
| Document: 0001193125-26-342371.txt | 0001193125-26-342371 |
| 8-K Data (Synthetic) | 0001193125-26-342371 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
Aug 10, 2026 7w ago | Press Release | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
May 11, 2026 20w ago | 8-K | $3.26 $2.82 | ▼ −13.50% | ▼ −11.77% | $2.87 (−12.12%) |
May 11, 2026 20w ago | Press Release | $3.26 $2.82 | ▲ +13.50% | ▲ +11.77% | $2.87 (+12.12%) |
Apr 24, 2026 23w ago | DEFA14A | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 24, 2026 23w ago | 8-K | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 13, 2026 24w ago | 8-K | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Apr 13, 2026 24w ago | Press Release | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Mar 13, 2026 29w ago | Press Release | $3.36 $3.21 | ▼ −4.46% | ▼ −8.05% | $2.87 (−14.73%) |
Mar 3, 2026 30w ago | Press Release | $3.82 $3.05 | ▼ −20.16% | ▼ −15.74% | $2.87 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access